Core Viewpoint - Anteris Technologies Global Corp. is actively participating in two major healthcare conferences, showcasing its commitment to advancing medical devices for heart function restoration [1][4]. Group 1: Conference Details - Anteris will present at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, featuring a fireside chat with analyst Joshua Jennings [2]. - The Barclays 28th Annual Healthcare Conference will take place on March 10, 2026, with a fireside chat led by analyst Matt Miksic [3]. - Both conferences will include 1x1 meetings and will be accessible via webcasts, which will be archived for up to 90 days [2][3]. Group 2: Company Overview - Anteris Technologies is a global structural heart company focused on designing and commercializing innovative medical devices [4]. - The company is headquartered in Australia and has a significant operational presence in Minneapolis, USA, emphasizing a science-driven approach [4]. - Anteris' lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate normal aortic blood flow [5].

Core Insights - Edwards Lifesciences is a leading company in the medical technology sector, focusing on heart valve therapies and critical care monitoring, particularly for structural heart diseases like aortic stenosis and mitral regurgitation [1] Company Performance - On December 4, 2025, BTIG upgraded Edwards Lifesciences to a "Buy" recommendation, with the stock priced at $85.78, reflecting confidence in the company's sustainable growth strategy and strong market position [2] - BTIG also raised the price target for Edwards Lifesciences from $100 to $103, indicating optimism about the company's ability to leverage emerging opportunities and expand its market presence [3] - The stock has shown resilience, currently priced at $85.78, with a recent increase of 2.14%, and has fluctuated between $65.94 and $87.40 over the past year, demonstrating stable performance [4] Market Position - Edwards Lifesciences has a market capitalization of approximately $50.37 billion, highlighting its significant presence in the medical technology industry [5] - The company has a trading volume of 2,385,439 shares, indicating strong investor interest and solidifying its leadership in heart valve therapies and critical care solutions [5]